Recent Investment Analysts’ Ratings Updates for Sage Therapeutics (SAGE)

Sage Therapeutics (NASDAQ: SAGE) recently received a number of ratings updates from brokerages and research firms:

• 10/31/2024 – Sage Therapeutics was downgraded by analysts at StockNews.com from a “hold” rating to a “sell” rating.
• 10/30/2024 – Sage Therapeutics had its price target lowered by analysts at Scotiabank from $17.00 to $14.00. They now have a “sector outperform” rating on the stock.
• 10/30/2024 – Sage Therapeutics had its “overweight” rating reaffirmed by analysts at Piper Sandler. They now have a $26.00 price target on the stock, down previously from $52.00.
• 10/30/2024 – Sage Therapeutics had its price target lowered by analysts at HC Wainwright from $25.00 to $14.00. They now have a “neutral” rating on the stock.
• 10/30/2024 – Sage Therapeutics had its price target lowered by analysts at Oppenheimer Holdings Inc. from $9.00 to $8.00. They now have a “market perform” rating on the stock.
• 10/30/2024 – Sage Therapeutics had its price target lowered by analysts at Truist Financial Co. from $13.00 to $8.00. They now have a “hold” rating on the stock.
• 10/30/2024 – Sage Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/17/2024 – Sage Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/10/2024 – Sage Therapeutics had its “market perform” rating reaffirmed by analysts at Raymond James.
• 10/9/2024 – Sage Therapeutics had its price target lowered by analysts at Bank of America Co. from $11.00 to $6.00. They now have an “underperform” rating on the stock.
• 10/9/2024 – Sage Therapeutics had its price target lowered by analysts at Wedbush from $9.00 to $8.00. They now have a “neutral” rating on the stock.
• 10/9/2024 – Sage Therapeutics had its “neutral” rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
• 10/9/2024 – Sage Therapeutics had its price target lowered by analysts at Robert W. Baird from $13.00 to $9.00. They now have a “neutral” rating on the stock.
• 10/8/2024 – Sage Therapeutics had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
• 10/4/2024 – Sage Therapeutics was downgraded by analysts at Royal Bank of Canada from an “outperform” rating to a “sector perform” rating. They now have a $4.00 price target on the stock, down previously from $10.00.

Sage Therapeutics Stock Down 5.6 %

Sage Therapeutics stock traded down $0.35 during trading hours on Tuesday, hitting $5.95. The stock had a trading volume of 113,935 shares, compared to its average volume of 966,113. Sage Therapeutics, Inc. has a fifty-two week low of $5.64 and a fifty-two week high of $28.26. The company has a market cap of $363.96 million, a PE ratio of -1.07 and a beta of 0.92. The company has a 50-day moving average of $7.18 and a two-hundred day moving average of $9.57.

Sage Therapeutics (NASDAQ:SAGE) last posted its earnings results on Tuesday, October 29th. The biopharmaceutical company reported ($1.53) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.52) by ($0.01). The business had revenue of $11.87 million during the quarter, compared to the consensus estimate of $10.80 million. Sage Therapeutics had a negative net margin of 317.29% and a negative return on equity of 50.29%. The business’s revenue was up 337.1% compared to the same quarter last year. During the same period in the previous year, the firm earned ($2.81) EPS. As a group, analysts forecast that Sage Therapeutics, Inc. will post -6.5 EPS for the current fiscal year.

Hedge Funds Weigh In On Sage Therapeutics

Several institutional investors have recently bought and sold shares of the business. Bellevue Group AG raised its position in shares of Sage Therapeutics by 27.1% during the first quarter. Bellevue Group AG now owns 4,465,544 shares of the biopharmaceutical company’s stock worth $83,684,000 after acquiring an additional 952,193 shares during the last quarter. Federated Hermes Inc. acquired a new stake in shares of Sage Therapeutics during the 2nd quarter worth approximately $7,281,000. Renaissance Technologies LLC raised its stake in shares of Sage Therapeutics by 1,476.6% during the second quarter. Renaissance Technologies LLC now owns 553,396 shares of the biopharmaceutical company’s stock worth $6,010,000 after buying an additional 518,296 shares during the last quarter. Cubist Systematic Strategies LLC lifted its holdings in Sage Therapeutics by 831.2% in the second quarter. Cubist Systematic Strategies LLC now owns 489,089 shares of the biopharmaceutical company’s stock valued at $5,312,000 after buying an additional 436,566 shares during the period. Finally, Vanguard Group Inc. grew its holdings in Sage Therapeutics by 8.1% during the 1st quarter. Vanguard Group Inc. now owns 5,751,373 shares of the biopharmaceutical company’s stock worth $107,781,000 after acquiring an additional 432,013 shares during the period. Institutional investors own 99.22% of the company’s stock.

Sage Therapeutics, Inc, a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression.